|

Tacrolimus Clinical Trials

23 actively recruiting trials across 13 locations

▼ -1 trial since August 2026

Also known as: 109581-93-3, Advagraf, FK 506, FK-506, FK506 +8 more

Pipeline

Phase 1: 5Phase 2: 15Phase 1/2: 3

Top Sponsors

  • City of Hope Medical Center6
  • Memorial Sloan Kettering Cancer Center3
  • Fred Hutchinson Cancer Center3
  • M.D. Anderson Cancer Center2
  • Thomas Jefferson University1

Indications

  • Cancer22
  • Acute Myeloid Leukemia9
  • Myelodysplastic Syndrome8
  • Acute Lymphoblastic Leukemia7
  • Chronic Myelomonocytic Leukemia5

Duarte, California6 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 2
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

City of Hope Medical Center

Phase 2
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering at Basking Ridge (Consent only)

Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

New York, New York2 trials

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 2
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Houston, Texas2 trials

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M D Anderson Cancer Center

Phase 1/2
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

The University of Texas M. D. Anderson Cancer Center

Phase 2

Seattle, Washington2 trials

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Other1 trial

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Phase 1/2

Birmingham, Alabama1 trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

The University of Alabama at Birmingham

Phase 2

Palo Alto, California1 trial

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Stanford University

Phase 1

Washington D.C., District of Columbia1 trial

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Phase 2

Tampa, Florida1 trial

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Baltimore, Maryland1 trial

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Minneapolis, Minnesota1 trial

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Masonic Cancer Center at University of Minnesota

Phase 2

Portland, Oregon1 trial

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

OHSU Knight Cancer Institute

Phase 1

Philadephia, Pennsylvania1 trial

Two Step Haplo With Radiation Conditioning

Sidney Kimmel Cancer Center at Thomas Jefferson University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.